Esteva, F. J. Et Al. 2007. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. BREAST CANCER RESEARCH , vol.9, no.6 .

Esteva, F. J., Wang, J., Lin, F., Mejia, J. A., Yan, K., Altundag, K., ... Valero, V.(2007). CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. BREAST CANCER RESEARCH , vol.9, no.6.

Esteva, Francisco Et Al. "CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer," BREAST CANCER RESEARCH , vol.9, no.6, 2007

Esteva, Francisco J. Et Al. "CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer." BREAST CANCER RESEARCH , vol.9, no.6, 2007

Esteva, F. J. Et Al. (2007) . "CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer." BREAST CANCER RESEARCH , vol.9, no.6.

@article{article, author={Francisco J. Esteva Et Al. }, title={CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer}, journal={BREAST CANCER RESEARCH}, year=2007}